Abstract
Innovations in digital technologies have emerged digital therapeutics (DTx) as a novel therapeutic intervention. DTx hold potential as novel theragnostics for disorders with broad diagnostic spectra, including neurodevelopmental diseases (NDDs). In this review, we highlight challenging factors in the successful development and deployment of DTx for NDDs with respect to patients, medical professionals, and manufacturers. We also discuss the implications of these factors and future directions for revitalizing DTx development for NDDs.